scPharmaceuticals Inc. (SCPH)

Market Cap	304.83M +15.8%
Revenue (ttm)	49.97M +107.8%
Net Income	-91.72M
EPS	-1.77
Shares Out	53.76M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,898,632
Open	5.68
Previous Close	5.67
Day's Range	5.65 - 5.71
52-Week Range	1.94 - 6.28
Beta	0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2025

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company’s lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-de...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 17, 2017
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: SCPH
• Website: https://www.scpharmaceuticals.com

Financial Performance

In 2024, scPharmaceuticals's revenue was $36.33 million, an increase of 167.28% compared to the previous year's $13.59 million. Losses were -$85.15 million, 55.4% more than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error